Peptide Economy, DTC First
Neal G@nealgnyc
+3.0%
since Oct 3
The idea
I think peptides are expanding well beyond GLP-1 into a broader category spanning medicine and cosmetics, and I want exposure weighted toward the direct-to-consumer layer capturing that shift. The basket splits across telehealth platforms selling these treatments, beauty companies riding peptide skincare, the drugmakers themselves from incumbents to smaller pipeline names, and the manufacturing and supply chain that benefits regardless of which drug wins.
What it owns
- The platforms selling peptide and weight-loss treatments directly to consumers online capture the core shift in how these drugs reach patients. · Hims & Hers HealthIt is the most direct exposure to peptide and weight-loss treatments moving from clinics to consumer phones and must keep growing subscriber bases across both categories., LifeMDIt is a smaller, focused bet on selling weight-loss and peptide-related care through telehealth and depends on its GLP-1 patient growth and continued partnerships with drugmakers., GoodRx HoldingsIt is the marketplace for discount consumer drug purchases including GLP-1 programs, so it benefits when drugmakers use this channel to reach cash-paying patients., Teladoc HealthIt is the larger-scale play on virtual care expanding for weight-management programs, riding the same shift toward phone-based treatment prescription and management.26%
- The companies manufacturing peptide drugs themselves determine whether demand for these treatments keeps expanding beyond their original medical uses. · Eli LillyIt makes the peptide drugs anchoring this entire category and is building direct-to-consumer sales channels, so its success depends on demand expanding from diabetes into weight, heart, and other uses., Novo NordiskIt is the other major GLP-1 producer and demonstrates the category can sustain multiple giants, provided its existing drugs stay in demand and its pipeline keeps it competitive., AmgenIt is a larger drugmaker entering the peptide obesity market with a different injection frequency, representing a bet that the market is large enough to support a third major competitor., Viking TherapeuticsIt is a smaller pipeline play with GLP-1 candidates in both injection and oral forms, depending on clinical trial results or acquisition by a larger drugmaker to succeed., Structure TherapeuticsIt is pursuing peptide-like oral drugs, representing the moonshot scenario where injections give way to pills and reach retail shelves, contingent on clinical data supporting its candidates.24%
- Beauty and skincare brands using peptide formulations participate in the trend without facing prescription or regulatory risk. · e.l.f. BeautyIt brings peptide skincare to mass-market retail at accessible prices, capturing the diversification into cosmetics this take requires and relying on peptide products to drive growth., Ulta BeautyIt is the retail shelf where peptide skincare products get discovered and purchased, capturing upside from whatever brand's formulation gains traction in the category., Estée LauderIt competes in the prestige peptide skincare segment at higher margins, but this stake also requires evidence that the company's broader turnaround is progressing., CotyIt holds a diverse portfolio of skincare brands pursuing peptide formulations, providing low-cost exposure to cosmetic peptides if this skincare push grows faster than legacy categories decline.22%
- Peptide production capacity is a genuine bottleneck, and suppliers in this layer earn revenue regardless of which drugmaker or which drug ultimately wins market share. · West Pharmaceutical ServicesIt manufactures the stoppers and injector components nearly every injectable peptide needs, so it earns revenue regardless of which drugmaker prevails as long as injection volumes keep rising., Thermo Fisher ScientificIt supplies the equipment and services underlying peptide manufacturing, so it earns revenue as drugmakers invest in production capacity and synthesis throughout the broadening category., DanaherIt makes bioprocessing tools that feed the plants manufacturing peptides and related drugs, earning revenue on category growth without needing to pick a specific winner., RepligenIt is the purest small-cap bet on peptide manufacturing, selling purification and filtration equipment drugmakers need, and will swing harder than larger peers on capacity expansion orders.18%
- Cash10%